The best indicator for Copart (CPRT)
We backtested 20 indicators across daily, weekly and hourly charts on real Copart (CPRT) history. Here's what actually worked — risk-adjusted, out-of-sample, with costs.
EMA 50/200 Cross
On the daily chart, this is the strongest risk-adjusted edge we found for Copart (CPRT) over ~32.2 years — trailing buy-and-hold by 3.4% CAGR.
The winner on each chart
Every indicator, ranked
Ranked by Sharpe (risk-adjusted return). Hypothetical, fees included.
| # | Indicator | TF | CAGR | Sharpe | Max DD | Win | Trades | vs B&H |
|---|---|---|---|---|---|---|---|---|
| 1 | EMA 50/200 Cross ✓ | Daily | 14.5% | 0.59 | -52.5% | 62.5% | 16 | -3.4% |
| 2 | WaveTrend (8/6/4) ✓ | Daily | 12.6% | 0.59 | -59.2% | 74.8% | 123 | -5.3% |
| 3 | SMA 50/200 Cross ✓ | Daily | 12.6% | 0.55 | -55.6% | 57.1% | 21 | -5.4% |
| 4 | Money Flow Index ✓ | Daily | 9.9% | 0.55 | -52.5% | 69.0% | 42 | -8.1% |
| 5 | RSI Trend (>50) ✓ | Weekly | 12.0% | 0.54 | -55.9% | 44.6% | 83 | -5.7% |
| 6 | CCI ✓ | Daily | 9.7% | 0.51 | -65.1% | 75.9% | 162 | -8.2% |
| 7 | Rate of Change ✓ | Weekly | 9.6% | 0.48 | -47.1% | 46.9% | 98 | -8.1% |
| 8 | CCI ✓ | Weekly | 7.2% | 0.46 | -62.1% | 87.5% | 32 | -10.5% |
| 9 | EMA 20/50 Cross ✓ | Daily | 8.8% | 0.44 | -59.5% | 37.2% | 78 | -9.2% |
| 10 | Donchian Midline ✓ | Daily | 8.4% | 0.44 | -50.0% | 42.7% | 447 | -9.6% |
| 11 | ADX / DMI ✓ | Weekly | 7.7% | 0.43 | -45.2% | 51.2% | 41 | -10.0% |
| 12 | Donchian Breakout ✓ | Weekly | 7.8% | 0.42 | -60.7% | 53.6% | 28 | -10.0% |
| 13 | Heikin-Ashi Trend ✓ | Weekly | 7.2% | 0.41 | -47.4% | 51.4% | 288 | -10.5% |
| 14 | EMA 20/50 Cross ✓ | Weekly | 16.5% | 0.64 | -54.9% | 55.6% | 9 | -1.2% |
✓ = held up out-of-sample. Hypothetical, costs included. See methodology.
For Copart (CPRT), EMA 50/200 Cross on the daily timeframe gave the best balance of return and risk in our test. It still trailed buy-and-hold on raw return — but remember: this is a hypothetical backtest of a standard rule, not a recommendation. Markets change. See the methodology and disclaimer.
More stock
Get the weekly edge report
The best-performing indicator per asset, what changed this week, and the honest caveats — straight to your inbox.